scholarly journals Correlation of BMI and elevated liver enzyme levels with severity of fatty liver infiltration on ultrasound in Sangrur, Punjab

2019 ◽  
Vol 9 (2) ◽  
pp. 53-55
Author(s):  
Saloni ◽  
◽  
Gunjan Jindal ◽  
Keyword(s):  
Fatty Liver ◽  
Liver Enzyme ◽  
Elevated Liver Enzyme

scholarly journals Determining the Target Population That Would Most Benefit from Screening for Hepatic Fibrosis in a Primary Care Setting

Diagnostics ◽  
2021 ◽  
Vol 11 (9) ◽  
pp. 1605
Author(s):  
Su Hyun Park ◽  
Jong Hyun Lee ◽  
Dae Won Jun ◽  
Kyung A Kang ◽  
Ji Na Kim ◽  
...  
Keyword(s):  
Primary Care ◽  
Fatty Liver ◽  
Hepatic Fibrosis ◽  
Liver Enzyme ◽  
Elevated Liver Enzyme ◽  
Curve Analysis ◽  
Low Risk ◽  
Net Benefit ◽  
Diabetes Group ◽  
Decision Curve Analysis

Due to its high prevalence, screening for hepatic fibrosis in the low-risk population is called for action in the primary care clinic. However, current guidelines provide conflicting recommendations on populations to be screened. We aimed to identify the target populations that would most benefit from screening for hepatic fibrosis in clinical practice. This study examined 1288 subjects who underwent magnetic resonance elastography. The diagnostic performance of the Fibrosis-4 (FIB-4) index and NAFLD fibrosis score was compared in the following groups: (1) ultrasonography (USG)-diagnosed NAFLD, (2) elevated liver enzyme, (3) metabolic syndrome, (4) impaired fasting glucose, and (5) type 2 diabetes regardless of fatty liver. Decision curve analysis was performed to express the net benefit of groups over a range of probability thresholds (Pts). The diabetes group showed a better area under the receiver operating characteristic curve (AUROC: 0.69) compared with subjects in the USG-diagnosed NAFLD (AUROC: 0.57) and elevated liver enzyme (AUROC: 0.55) groups based on the FIB-4 index. In decision curve analysis, the diabetes group showed the highest net benefit for the detection of significant fibrosis across a wide range of Pts. Patients with diabetes, even in the absence of fatty liver, would be preferable for hepatic fibrosis screening in low-risk populations.

scholarly journals Factors Determining the Intensive Care Need in Help Syndrome & AFLP in Pregnancy

2021 ◽  
Vol 6 (2) ◽  
pp. 1-5
Author(s):  
Aydin Atis Alev ◽  
Keyword(s):  
Intensive Care ◽  
Fatty Liver ◽  
Liver Enzyme ◽  
Elevated Liver Enzyme ◽  
Mortality And Morbidity ◽  
Factors Affecting ◽  
Acute Fatty Liver ◽  
In Pregnancy

To compare factors affecting mortality and morbidity in HELLP (Hemolysis, Elevated Liver Enzyme Levels, and Low Platelets) syndrome & AFLP (Acute fatty liver of pregnancy).

scholarly journals Insufficienza renale acuta del postpartum: una diagnosi complessa?

2013 ◽  
Vol 25 (1) ◽  
pp. 26-31
Author(s):  
Giuseppe Gernone ◽  
Francesco Papagno ◽  
Vito Pepe ◽  
Francesco Soleti
Keyword(s):  
Fatty Liver ◽  
Plasma Exchange ◽  
Liver Enzyme ◽  
Elevated Liver Enzyme ◽  
Acute Fatty Liver

La diagnosi differenziale nei casi d'insufficienza renale acuta del postpartum associata ad anemia emolitica microangiopatica e trombocitopenia, include, tra le altre: pre-clampsia grave/eclampsia, grave eclampsia, la sindrome HELLP (Hemolysis, Elevated Liver enzyme, Low Platelet), la acute fatty liver of pregnancy (AFLP), la porpora trombotica trombocitopenica/sindrome emolitico-uremica associata alla gravidanza (TTP/aHUS), esordio acuto o flare di LES in gravidanza e la sindrome catastrofica da anticorpi antifosfolipidi (CAPS). Si tratta di condizioni potenzialmente pericolose per la vita data la presenza di disfunzione multiorgano. Il verificarsi di uno stato di ipercoagulabilità e la concentrazione decrescente di ADAMTS 13 in gravidanza e nel post-parto aumentano il rischio di sviluppare porpora trombotica trombocitopenica (TTP). Vi è però una notevole sovrapposizione riguardo la clinica ed i test di laboratorio tra queste condizioni, e quindi la diagnosi può essere un problema anche per clinici esperti. Tuttavia è importante stabilire un'accurata diagnosi poiché la gestione e le complicanze di tali sindromi possono essere differenti. Il caso presentato sottolinea la complessità connessa alla diagnosi differenziale dei quadri clinici che includono anemia emolitica microangiopatica e trombocitopenia connessi alla gravidanza ed il ruolo del plasma exchange nella loro gestione.

scholarly journals Non-alcoholic fatty liver disease in polycystic ovary syndrome women

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Young Bin Won ◽  
Seok Kyo Seo ◽  
Bo Hyon Yun ◽  
SiHyun Cho ◽  
Young Sik Choi ◽  
...  
Keyword(s):  
Risk Factors ◽  
Liver Disease ◽  
Fatty Liver ◽  
Liver Enzyme ◽  
Fatty Liver Disease ◽  
Polycystic Ovary ◽  
Insulin Level ◽  
University Hospital ◽  
Alcoholic Fatty Liver ◽  
Alcoholic Fatty Liver Disease

AbstractTo evaluate risk factors leading to non-alcoholic fatty liver disease (NAFLD) occurrence in polycystic ovarian syndrome (PCOS) women. A retrospective cohort study of a total of 586 women diagnosed with PCOS aged 13–35 years at the gynecology department at a university hospital was done to evaluate PCOS phenotype, metabolic syndrome (MetS) diagnosis, body composition, insulin sensitivity, sex hormones, lipid profile, liver function, and transient elastography (TE). In PCOS women with NAFLD compared to those without, MetS diagnosis (Hazard ratio [HR] 5.6, 95% Confidence interval [CI] 2.2–14.4, p < 0.01) and hyperandrogenism (HA) (HR 4.4, 95% CI 1.4–13.4, p = 0.01) were risk factors significantly associated with subsequent NAFLD occurrence, whereas 2-h insulin level in 75 g glucose tolerance test (GTT) (HR 1.2, 95% CI 0.5–2.5, p = 0.70) and body mass index (BMI) > 25 kg/m2 (HR 2.2, 95% CI 0.6–8.0, p = 0.24) was not. Among NAFLD patients who underwent TE, a higher number of MetS components indicated a worse degree of fibrosis and steatosis. MetS diagnosis and HA at PCOS diagnosis were risk factors associated with NAFLD, while 2-h insulin level in 75 g GTT and obesity were not. Although elevated aspartate aminotransferase levels were significant for NAFLD risk, liver enzyme elevations may not be present until late liver damage. Further prospective studies of PCOS women with MetS or HA are warranted to determine whether patients without liver enzyme elevations should undergo preemptive liver examinations.

scholarly journals Nonalcoholic Fatty Liver Disease in Canadian First Nations and Non-First Nations Patients

2016 ◽  
Vol 2016 ◽  
pp. 1-6 ◽  
Author(s):  
Julia Uhanova ◽  
Gerald Minuk ◽  
Federico Lopez Ficher ◽  
Natasha Chandok
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Nonalcoholic Fatty Liver Disease ◽  
First Nations ◽  
Liver Enzyme ◽  
Fatty Liver Disease ◽  
Clinical Laboratory ◽  
Tertiary Care ◽  
Tertiary Care Centre ◽  
Nonalcoholic Fatty Liver

Background.Features of nonalcoholic fatty liver disease (NAFLD) have yet to be described in the Canadian First Nations (FN) population. The aim of this study was to compare the prevalence, severity, and outcome of NAFLD in FN versus non-FN patients at an urban, tertiary care centre.Methods.Adults with NAFLD and no additional liver disease were identified in a prospectively derived database at the University of Manitoba. Demographic, clinical, laboratory, imaging, and histologic data were analyzed.Results.482 subjects fulfilled diagnostic criteria for NAFLD, including 33 (7%) FN. Aside from rural residence, diabetes and cholestasis being more common in FN patients, the ages, gender distributions, clinical and radiologic features, and liver enzyme/function test results were similar in the two cohorts. Noninvasive tests of fibrosis (APRI and NAFLD fibrosis scores) were also similar in the two cohorts. There were no significant differences in liver enzyme or function tests in either cohort after approximately three years of follow-up.Conclusion.Compared to the prevalence of FN persons in the general population of this study site (10–15%), FN patients were underrepresented in this NAFLD population. The severity and progression of liver disease in FN patients appear to be similar to those in non-FN patients.

scholarly journals Case Report: Clinical Features of Congenital Portosystemic Shunts in the Neonatal Period

2021 ◽  
Vol 9 ◽  
Author(s):  
Suhua Xu ◽  
Peng Zhang ◽  
Liyuan Hu ◽  
Wenhao Zhou ◽  
Guoqiang Cheng
Keyword(s):  
Liver Transplantation ◽  
Conservative Treatment ◽  
Liver Enzyme ◽  
Neonatal Period ◽  
Elevated Liver Enzyme ◽  
Clinical Symptoms ◽  
Treatment Options ◽  
Type Ii ◽  
Neonatal Cholestasis ◽  
Portosystemic Shunts

Objective: The aim of this single-center retrospective study was to analyze the clinical characteristics, treatment options, and course of neonatal-onset congenital portosystemic shunts (CPSS).Methods: We included all patients with CPSS who presented with clinical symptoms within the neonatal period in our institution between 2015 and 2020.Results: Sixteen patients were identified, including 13 patients with intrahepatic portosystemic shunts (IPSS) and three patients with extrahepatic portosystemic shunts (EPSS). The median age of diagnosis was 16 days (range prenatal 24 weeks−12 months). Hyperammonemia (60%), neonatal cholestasis (44%), elevated liver enzyme (40%), hypoglycemia (40%), thrombocytopenia (38%), and coagulation abnormalities (23%) appeared in neonatal CPSS. Twelve patients (75%) presented with congenital anomalies, of which congenital heart disease (CHD) (44%) was the most common. Thirteen patients with IPSS initially underwent conservative treatment, but two of them were recommended for the catheter interventional therapy and liver transplantation, respectively, due to progressive deterioration of liver function. Spontaneous closure occurred in nine patients with IPSS. The shunt was closed using transcatheter embolization in one patient with EPSS type II. Another patient with EPSS type II underwent surgical treatment of CHD firstly. The remaining patient with EPSS type Ib received medical therapy and refused liver transplantation.Conclusion: Hyperammonemia, neonatal cholestasis, elevated liver enzyme, hypoglycemia, and thrombocytopenia are the main complications of neonatal CPSS. Moreover, CPSS is associated with multiple congenital abnormalities, especially CHD. Intrahepatic portosystemic shunts may close spontaneously, and conservative treatment can be taken first. Extrahepatic portosystemic shunts should be closed to prevent complications.

Sign in / Sign up

Export Citation Format

Share Document